1. Teclistamab versus real-world physicians choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
- Author
-
Krishnan, Amrita, Nooka, Ajay, Chari, Ajai, Garfall, Alfred, Martin, Thomas, Nair, Sandhya, Lin, Xiwu, Qi, Keqin, Londhe, Anil, Pei, Lixia, Ammann, Eric, Kobos, Rachel, Smit, Jennifer, Parekh, Trilok, Marshall, Alexander, Slavcev, Mary, and Usmani, Saad
- Subjects
B-cell maturation antigen ,MajesTEC-1 ,bispecific antibody ,comparative effectiveness ,indirect treatment comparison ,Humans ,Multiple Myeloma ,Treatment Outcome ,Dexamethasone ,Antineoplastic Agents ,Physicians ,Antineoplastic Combined Chemotherapy Protocols - Abstract
Aim: We compared the effectiveness of teclistamab versus real-world physicians choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59-1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33-0.56]; p
- Published
- 2023